Loading
Lab-grown mini-tumours usually contain only cancer cells. Adding the patient's own immune cells lets researchers test immunotherapy outside the body.
Air-liquid interface organoids and reconstituted co-cultures preserve or restore tumour-infiltrating lymphocytes and myeloid cells, and have been used to model checkpoint blockade responses and to expand tumour-reactive T cells. Standardising these systems, including autologous peripheral blood mononuclear cell co-cultures with defined killing readouts, would give an ex vivo assay for immunotherapy and cell therapy that plain organoids cannot provide.
Shares Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, TIL therapy, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients, No one can predict who responds to immunotherapy.